Clarity is a personalised medicine company focused on the treatment of serious diseases. The Company is a leader in innovative radiopharmaceuticals, developing targeted therapies for the treatment of cancer and other serious diseases in adults and children.

Clarity’s platform technology allows peptides and antibodies to be radiolabeled for visualisation using PET imaging and therapy. The human imaging data generated provides information on whether the drug reaches the desired disease target in a patient. This information enables a personalised approach by only treating those patients that are likely to respond to therapy and excluding those that won’t. This precision medicine approach is at the forefront of drug development.

Pharmaceutical Development

Clarity develops personalised medicine diagnostic imaging and therapeutic products. By using its proprietary technology, Clarity is developing next generation theranostic solutions for serious diseases, such as cancer, that are not well treated by current therapies.

Clarity Pharmaceuticals actively manages an in-house drug development program, with its first drug SARTATE™, an oncology theranostic (diagnostic and therapy), in clinical trials for meningioma and neuroendocrine tumours in adult patients. SARTATE™ will also potentially allow better treatment of paediatric cancers and is in clinical trials for neuroblastoma, an aggressive childhood cancer. Clarity will complete the commercial development of SARTATE™ as a product and further realise the potential of other pipeline products using Clarity’s platform SAR Technology in other cancers.